XORTX Therapeutics Inc
XTSX:XRTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
XORTX Therapeutics Inc
Interest Income Expense
XORTX Therapeutics Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XORTX Therapeutics Inc
XTSX:XRTX
|
Interest Income Expense
$601.5k
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Interest Income Expense
-$1.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Interest Income Expense
-CA$208.4m
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-115%
|
|
|
Cronos Group Inc
TSX:CRON
|
Interest Income Expense
$10.9m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
13%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Interest Income Expense
$5.7m
|
CAGR 3-Years
154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Interest Income Expense
-CA$4.7m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
XORTX Therapeutics Inc
Glance View
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
See Also
What is XORTX Therapeutics Inc's Interest Income Expense?
Interest Income Expense
601.5k
USD
Based on the financial report for Dec 31, 2025, XORTX Therapeutics Inc's Interest Income Expense amounts to 601.5k USD.
What is XORTX Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-44%
Over the last year, the Interest Income Expense growth was -45%. The average annual Interest Income Expense growth rates for XORTX Therapeutics Inc have been -44% over the past three years .
